You might also like
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates to address the underlying genetic causes of diseases. The company aims to transform healthcare by reducing the burdens associated with treatment and improving patient outcomes. Lexeo does not currently sell commercial products but is advancing a pipeline of gene therapy candidates targeting cardiovascular and neurological diseases.
- LX2006 - Targets Friedreich ataxia cardiomyopathy and is currently in a Phase 1/2 clinical trial. It has received multiple FDA designations, including Rare Pediatric Disease, Orphan Drug, Fast Track, and RMAT, as well as Orphan Medicinal Product designation from the European Commission.
- LX2020 - Focuses on arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene. It is in a Phase 1/2 clinical trial and has received Fast Track and Orphan Drug designations from the FDA.
- LX1001 - Aims to treat APOE-associated Alzheimer’s disease, leveraging gene therapy approaches to address this neurological condition.
- Other Pipeline Programs - Includes additional gene therapy candidates targeting various cardiovascular and neurological diseases.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
R. Nolan Townsend ExecutiveBoard | Chief Executive Officer | Board Member at Arbor Biotechnologies; Member of the Board of Directors at Biotechnology Innovation Organization | R. Nolan Townsend has served as the Chief Executive Officer of Lexeo Therapeutics since January 2020 and is a member of its board of directors. He has extensive leadership experience in the biopharmaceutical sector, with previous roles at Pfizer in rare disease and gene therapy divisions. | View Report → |
Eric Adler Executive | Chief Medical Officer and Head of Research | Eric Adler, M.D. serves as the Chief Medical Officer and Head of Research at LXEO since February 2024, having previously served as the Chief Scientific Officer from August 2022 to February 2024. | ||
Jenny R. Robertson Executive | Chief Business and Legal Officer | Jenny R. Robertson, J.D., is the Chief Business and Legal Officer at LXEO since February 2024. She previously served as Chief Legal and Administrative Officer and Senior Vice President, General Counsel and Head of People at LXEO. Prior to joining LXEO, she held senior legal roles at Pfizer Inc. and worked in private practice. | ||
Sandi See Tai Executive | Chief Development Officer | Sandi See Tai is the Chief Development Officer at Lexeo Therapeutics since February 5, 2024. She previously served as Senior Vice President, Clinical Development and Operations at Lexeo Therapeutics from October 2023 to February 2024. | ||
Brenda Cooperstone Board | Member of the Board of Directors | Member of the Board of Directors at Senti Biosciences, Inc. since October 2019; Member of the Board of Directors at Gandeeva Therapeutics since January 2023 | Brenda Cooperstone, M.D. has been serving as a board member at LXEO since August 2023 and holds the title of Class III Director with her current term expiring in 2026. She also serves on the Compensation Committee and the Nominating and Governance Committee at LXEO. | |
Paula HJ Cholmondeley Board | Member of the Board of Directors | CEO of Sorrel Group; Part-Time Faculty Member at NACD; Board Member at Bank OZK; Board Member at Terex Corporation | Paula HJ Cholmondeley has served on LXEO's board since November 2021 as a Class III Director with a term expiring in 2026. She brings extensive financial leadership and governance expertise from roles including serving as CEO of Sorrel Group since January 2004 and as a Part-Time Faculty Member at NACD since June 2008. | |
Steven Altschuler Board | Chairman of the Board of Directors | Managing Director, Healthcare Ventures at Ziff Capital Partners; Director of WW International, Inc.; Director of 89bio, Inc. | Steven Altschuler, M.D. has served as the Chairman of the Board of Directors at LXEO since January 2021, serving in a non-employee director capacity to maintain independence between the board and the executive team. His extensive background in healthcare leadership further reinforces his commitment to strong governance. | |
Tim Van Hauwermeiren Board | Independent, Non-Executive Director | CEO of argenx SE; Board Member of argenx SE; Board Member of iTeos Therapeutics, Inc. | Tim Van Hauwermeiren is a seasoned biotech leader who was appointed as an independent, non-executive director at LXEO on July 5, 2024. He co-founded and has served as CEO of argenx SE since July 2008 and holds additional board roles, underscoring his extensive experience and leadership in the industry. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Astellas Pharma Inc. | Developing clinical stage gene therapy programs targeting diseases similar to those addressed by LX2006, a product candidate for FA cardiomyopathy. |
Engaged in clinical stage gene therapy programs that overlap with the therapeutic focus of LX2006. | |
Collaborating with Neurocrine Biosciences, Inc. on clinical stage gene therapy programs relevant to LX2006's target indications. | |
Partnering with Voyager Therapeutics, Inc. on gene therapy programs that compete with LX2006. | |
Conducting early-stage gene editing discovery efforts that may compete with LXEO's gene therapy initiatives. | |
Tune Therapeutics, Inc. | Involved in early-stage gene editing discovery efforts that overlap with LXEO's therapeutic focus. |
Developing CTI-1601, a clinical stage product candidate for FA, which competes with LX2006. | |
Advancing DT-216P2, a product candidate for FA, which competes with LX2006. | |
Submitted a new drug application for vatiquinone to the FDA, targeting FA, which competes with LX2006. | |
Acquired Reata Pharmaceuticals, Inc. and is commercializing Skyclarys (omaveloxolone), an FDA-approved treatment for FA. | |
Developing an AAV-based gene therapy candidate for PKP2-ACM, competing with LX2020. | |
Working on an AAV-based gene therapy candidate for PKP2-ACM, which competes with LX2020. |
Recent press releases and 8-K filings for LXEO.
- Clinical and regulatory updates: The company announced enhanced FDA alignment for accelerated development of LX2006 and provided positive early data for LX2020, including favorable safety and a 67% reduction in PVCs in one participant.
- Financial performance: Q4 2024 results showed a net loss of $25.9 million with increased R&D and G&A expenses, while a robust cash position of $128.5 million is expected to fund operations into 2027.
- Cardiac gene therapy progress: Advancing programs for FA cardiomyopathy (LX2006) with robust frataxin expression and a promising average 14% improvement in LV mass index in Friedreich’s ataxia, exceeding the FDA threshold .
- Arrhythmogenic cardiomyopathy development: Completed enrollment of Cohort 1 in the PKP2-ACM (LX2020) study with initial safety and biomarker readouts expected in early 2025 .
- Alzheimer’s gene therapy update: A 15‑patient dose escalation study in APOE4 homozygous patients delivering the APOE2 gene showed significant reductions in tau biomarkers without ARIA events, with partnering discussions underway .
- Upcoming milestones: High‑dose readouts by mid‑2025, registrational study initiation by late‑2025/early‑2026, and additional interim clinical milestones in early Q2 2025 .
- Financial strength: Approximately $157M in cash and marketable securities, ensuring a funding runway into 2027 .
- Lexeo Therapeutics advances its strategic focus in cardiac gene therapy, targeting significant unmet needs in FA cardiomyopathy and PKP2-ACM via dual clinical programs with LX2006 and LX2020.
- Lead candidate LX2006 is demonstrating promising clinical activity, favorable safety signals, and regulatory alignment for accelerated approval.
- The pipeline features multiple programs with updated clinical milestones for 2025, including robust endpoints such as LVMI reduction and increased frataxin expression.
- Ongoing studies are expanding enrollment and performing detailed biomarker evaluations across both Lexeo-sponsored and investigator-initiated trials.